Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on results. The company lowered its full-year revenue and gross-margin outlook and suspended adjusted
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing s...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to ...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Thursday after market hours. Here’s what you need to know. Myriad Genet...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Myriad Genetics has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $5.66. The stock also fell short of t...
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th...
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 9.2% in the morning session after the company expanded the availability...
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Myriad Genetics began 2026 with results that fell short of Wall Street’s expectations, as the company posted modest year-over-year sales growth but missed on...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Tuesday after market close. Here’s what you need to know. Myriad Geneti...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
